https://www.indianpharmapost.com/astec-lifesciences-q1-fy2023-consolidated-pat-drops-to-rs-1139-cr-127242022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/dabur-launches-dabur-himalayan-shilajit-127362022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/sun-pharma-and-cosmo-announce-territory-expansion-of-license-and-supply-agreements-for-winlevi-127352022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/zydus-receives-final-approval-from-the-usfda-for-bisoprolol-fumarate-tablets-127342022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/sanofi-india-q2-cy2022-pat-drops-495-to-rs-1204-cr-127332022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/suven-life-sciences-posts-q1fy23-consolidated-loss-at-rs-1632-cr-127322022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/healthcare-triangle-launches-in-singapore-leveraging-ai-and-cloud-in-asia-pacific-markets-127312022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/cadila-pharma-bags-rising-digital-star-award-at-digipharmax-127302022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/urinary-incontinence-2nd-biggest-reason-for-limited-mobility-in-elderly-survey-127292022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/lupin-receives-approval-from-us-fda-for-azilsartan-medoxomil-tablets-127282022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/glaxosmithkline-pharmaceuticals-q1fy23-consolidated-pat-at-rs-11928-cr-127272022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/vikas-lifecare-consolidated-q1fy23-pat-at-rs-259-cr-127262022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/krsnaa-diagnostics-bags-large-tender-in-maharashtra-127252022-07-26T00:00:00+05:30always0.9https://www.indianpharmapost.com/funds-for-rd-in-drug-discovery-and-manufacturing-pib-127372022-07-26T00:00:00+05:30always0.9